A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With Dyslipidemia
Obesity, Hyperlipidemia, Hypertriglyceridemia
About this trial
This is an interventional treatment trial for Obesity focused on measuring Obesity, Dyslipidemia, Hyperlipidemia, Triglyceride, HDL, LDL, Diabetes
Eligibility Criteria
Inclusion Criteria: A Body Mass Index (BMI) >= 27 kg/m^2 and <50 kg/m^2 Stable weight at least four months prior to the first enrollment visit Diagnosis of dyslipidemia (serum triglycerides representative of mild to moderate hypertriglyceridemia and low HDL or high LDL) Patients on lipid lowering medication should be on monotherapy with the same drug for at least 4 months and on the same dose for at least 2 months prior to the first enrollment Female patients must be postmenopausal for at least 1 year, surgically incapable of childbearing, practicing abstinence, or practicing an acceptable method of contraception (requires negative pregnancy test) Exclusion Criteria: Contraindication or hypersensitivity to topiramate Pregnancy, nursing or women who plan to become pregnant during the study Enrollment fasting triglycerides <175 or >= 1000 mg/dL, and/or LDL >= 190 mg/dL Hyperlipidemia secondary to known disease Other significant medical conditions such as cardiovascular or liver disease